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CD8 T cells play a key role in defense against the
intracellular parasite Toxoplasma, but why certain
CD8 responses are more potent than others is not
well understood. Here, we describe a parasite anti-
gen, ROP5, that elicits a CD8 T cell response in
genetically susceptible mice. ROP5 is secreted via
parasite organelles termed rhoptries that are injected
directly into host cells during invasion, whereas the
protective, dense-granule antigen GRA6 is constitu-
tively secreted into the parasitophorous vacuole.
Transgenic parasites in which the ROP5 antigenic
epitope was targeted for secretion through dense
granules led to enhanced CD8 T cell responses,
whereas targeting the GRA6 epitope to rhoptries
led to reduced CD8 responses. CD8 T cell responses
to the dense-granule-targeted ROP5 epitope re-
sulted in reduced parasite load in the brain. These
data suggest that the mode of secretion affects the
efficacy of parasite-specific CD8 T cell responses.INTRODUCTION
CD8 T cells are key for the control of intracellular pathogens,
including the protozoan parasite Toxoplasma gondii. T. gondii in-
fects a wide array of warm-blooded hosts, including one-third of
humans worldwide (Carruthers, 2002; Montoya and Liesenfeld,
2004), but typically causes little pathology, due in part to a robust
T cell response (Brown and McLeod, 1990; Denkers and Gazzi-
nelli, 1998; Hakim et al., 1991; Lindberg and Frenkel, 1977).
However, not all CD8 T cell responses are equally effective in
controlling the parasite, as dramatically illustrated by the differ-
ential sensitivity to infection in two inbred mouse strains,
BALB/c and C57BL/6 (B6). BALB/c mice show strong resistance
to infection due to the presence of the protective MHC class I
allele H-2Ld, whereas B6 mice, which lack this particular allele,1716 Cell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authorsare highly sensitive (Brown et al., 1995; Brown and McLeod,
1990; Suzuki et al., 1991, 1994). We recently showed that the
protective effect of MHC class I H-2Ld is due to a potent CD8
T cell response directed against a single parasite protein,
GRA6 (Blanchard et al., 2008). H-2Ld-GRA6-specific T cells ac-
count for the majority of CD8 T cells in the brains of infected
H-2d mice and effectively control the parasite load. In contrast,
B6 (H-2b) mice exhibit much higher parasite loads in the brain
and eventually succumb to infection despite the presence of
parasite-specific CD8 T cells (Schaeffer et al., 2009). Under-
standing why particular CD8 T cell responses predominate
over others, and why some responses provide more effective
protection is critical for designing improved vaccines and other
therapies against intracellular pathogens.
One factor that may influence the immunogenicity and immu-
noprotection of potential CD8 antigens is the intracellular
pathway by which pathogen-derived antigens are processed
and presented in infected host cells. For cytosolic antigens,
such as many viral antigens, presentation occurs via the clas-
sical class I MHC presentation pathway. In this pathway, pro-
teins are degraded in the host cytosol by proteasomes and the
resulting peptides are transported into the endoplasmic reticu-
lum (ER) via the TAP transporter, receive a final trimming by
the ERRAP, are loaded onto MHC class I, and finally are trans-
ported to the surface as peptide-MHC complexes for recognition
by a CD8 T cell. In contrast, for pathogen proteins that enter the
cell via phagocytosis, antigen presentation occurs by an alterna-
tive ‘‘cross-presentation’’ pathway that requires a phagosome in
addition to the ER vesicular transport step (Joffre et al., 2012).
The importance of antigen compartmentalization for the CD8
T cell response is illustrated by the protective response to intra-
cellular bacteria that occurs when the antigen is secreted into the
cytosol, but not when the antigen is retained inside the bacteria
(Shen et al., 1998).
For intracellular parasites, the pathways by which potential
antigens traffic from the pathogen into the host cell may also
impact CD8 T cell responses. For example, T. gondii resides
within a specialized nonfusogenic compartment, the parasito-
phorous vacuole, which restricts the movement of material
Figure 1. T. gondii-Specific CD8 T Cell
Responses in B6 Mice Ex Vivo and after
In Vitro Expansion
C57BL/6 mice were immunized with irradiated
T. gondii tachyzoites. Splenocytes were har-
vested from mice at 2 weeks postimmunization,
and T. gondii-specific CD8 and CD4 T cell re-
sponses were measured by intracellular cytokine
staining for IFN-g. APCs ± T. gondii were used as
stimulators for ex vivo and in vitro restimulations.
(A–C) Ex vivo and in vitro restimulation results are
shown as (A) representative flow-cytometry plots
and (B and C) plots depicting the expansion of
CD8 T cells (B) and CD4 T cells (C) over the course
of ten in vitro restimulations. Data are represen-
tative of three experiments.
(D) LacZ response of subcloned CD8 hybridoma
(BTg45Z) after an overnight culture with wild-type
APCs ± T. gondii or APCs blocked with antibodies
against H-2Kb or H-2Db MHC I molecules +
T. gondii. Data are representative of at least two
independent experiments.into the host cytosol and thus poses a barrier to antigen pre-
sentation. Nevertheless, studies with model antigens have
shown that proteins that are constitutively secreted into the
parasitophorous vacuole lumen via parasite organelles termed
dense granules can elicit strong CD8 T cell responses (Gregg
et al., 2011; Gubbels et al., 2005). Moreover, the potent endog-
enous CD8 antigen GRA6 is also constitutively secreted via
dense granules (Blanchard et al., 2008). Toxoplasma also pos-
sesses distinct secretory organelles termed rhoptries that are
injected directly into the host cell during productive and abor-
tive invasion events (Blader and Saeij, 2009; Boothroyd and Du-
bremetz, 2008; Koshy et al., 2012), and this distinct spatial and
temporal pattern of secretion could affect the ability of a para-
site protein to be presented by MHC class I. All endogenous
T. gondii CD8 antigens identified to date possess secretory
signals, and include both dense-granule and rhoptry proteins
(Frickel et al., 2008; Wilson et al., 2010; Blanchard et al.,
2008). However, how the mode of secretion of potential
T. gondii antigens affects the nature of the CD8 T cell response
has not been investigated.
A comparison between the immunodominant, protective
H-2Ld-GRA6 response and the endogenous T cell response
from susceptible H-2b mice should reveal clues about what con-
stitutes an optimal CD8 T cell response. Aside from GRA6, all
other defined endogenous MHC-I-restricted T. gondii antigens
have been identified with the use of prediction strategies (Frickel
et al., 2008; Khan et al., 1988, 1994; Wilson et al., 2010).
These approaches, while useful, may miss many endogenous
responses that do not fit into a given set of assumptions. In
contrast, the alternative approach of using T cells from infected
mice to probe expression libraries provides a relatively unbiased
way to characterize endogenous T cell responses (Blanchard
et al., 2008; Malarkannan et al., 2001).
Here, we used an expression-cloning approach to charac-
terize the CD8 T cell response in H-2b mice, which led to the
identification of a nonamer peptide, YAL9, derived from theCrhoptry-targeted parasite protein ROP5. In comparison with
the H-2Ld-GRA6 response, the H-2Db-ROP5 (YAL9) response
accounts for a relatively small proportion of the endogenous
CD8 T cell response to the parasite and does not confer strong
protection. To test the impact of regulated secretion on the
T cell response, we engineered parasites in which the YAL9
epitope from ROP5 was altered from its normal rhoptry targeting
to secretion via dense granules, and we examined the impact
of this alteration on the T cell response. Redirecting the ROP5
epitope to the dense granules led to a dramatic increase in the
number and protective capacity of H-2Db-ROP5-specific
T cells, and to a reduced cyst burden in chronically infected
mice. Conversely, retargeting the T cell-stimulatory epitope
from GRA6 (HF10) for secretion via rhoptries led to a substan-
tially reduced T cell response. Our data suggest that the mode
of protein secretion can have a dramatic effect on the magnitude
and efficacy of the CD8 T cell response, with important implica-
tions for immunity to T. gondii and related malaria-causing intra-
cellular parasites.
RESULTS
T. gondii-ImmunizedC57BL/6MiceExhibit PotentCD4T
Cell Responses but Weaker CD8 T Cell Responses
To characterize the T cell response in C57BL/6 (B6, H-2b)
mice, we immunized animals with irradiated tachyzoites of
the type II T. gondii strain Prugniaud (Pru) and examined
T. gondii-specific CD4 and CD8 T cell responses ex vivo at
2 weeks. In contrast to H-2d mice, in which the CD8 T cell
response dominates over the CD4 T cell response (Blanchard
et al., 2008), B6 mice generated a robust CD4 T cell response
but a weaker CD8 response toward T. gondii (Figure 1A, top
panels; Grover et al., 2012). To selectively expand the CD8
T cells, we used MHC class II-deficient dendritic cells (DCs)
as antigen-presenting cells (APCs) for in vitro restimulations.
The T. gondii-specific CD8 T cells progressively expandedell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authors 1717
Figure 2. BTg45Z Hybridoma Recognizes
the ROP5 Rhoptry Protein
(A) T. gondii cDNA library was screened to identify
the antigen recognized by BTg45Z. Two cDNA
pools (pTg8E6 and pTg13B7) stimulated the lacZ
response of the hybrid.
(B) pTg8E6 was further fractionated to identify a
positive cDNA clone pTg8E6.1. The BTg45Z
response to pTg8E6.1 was antigen specific and
MHC restricted.
(C) T. gondii database (http://toxodb.org/toxo/)
BLAST search results revealed that the antigenic
cDNA clone pTg8E6.1 encoded a truncated
version of the T. gondii protein, TGMe49_018080
(Rhoptry kinase family protein 5). Alignment of the
amino acid sequence encoded by the truncated
cDNA clone pTg8E6.1 as compared with the full-
length polymorphic clones ROP5IIA and ROP5IIC
(Reese et al., 2011) and pTg13B7 is depicted
here. () represents missing amino acids in the
sequence, (*) represents alignment, and (: or gap)
represents alignment between ROP5IIC and
pTg8E6.1 and pTg13B7.
See also Figure S1.over successive in vitro restimulation cultures (Figures 1A,
lower panels, 1B, and 1C).
Generation of a T. gondii-Specific CD8 T Cell Hybridoma
To further characterize the T. gondii-specific CD8 T cell response
at a clonal level, we generated T. gondii-specific, lacZ-inducible
CD8 T cell hybridomas as described previously (Karttunen et al.,
1992; Sanderson and Shastri, 1994). One such hybridoma,
referred to as BTg45Z, produced lacZ when cocultured with
bone-marrow-derived DCs (BMDCs) infected with T. gondii (Fig-
ure 1D) and this response was blocked by anti-H-2Db, but not
anti-H-2Kb, monoclonal antibody. Thus, the BTg45Z hybridoma1718 Cell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authorswas T. gondii specific and restricted by
the H-2Db MHC class I molecule.
ROP5 Is the Antigenic Protein
Recognized by CD8 T Cell
Hybridoma
We identified the T. gondii antigenic pro-
tein by expression cloning. A T. gondii-
derived cDNA expression library was
screened for BTg45Z-stimulating genes
(Figure S1; Blanchard et al., 2008).
APCs transfected with two cDNA pools
(pTg8E6 and pTg13B7) stimulated the
BTg45Z T cell hybrid (Figure 2A). Frac-
tionation of the cDNA pools yielded
an antigenic active clone, pTg8E6.1 (Fig-
ure 2B), that encoded a member of the
rhoptry protein 5 (ROP5) family of pro-
teins. The ROP5 locus is located on chro-
mosome XII and encodes a polymorphic
family of four to ten pseudokinases that
differ both between Toxoplasma strainsand between individual genes within a single cluster (Reese
et al., 2011). Sequence comparison with different polymorphic
versions of ROP5 in the type II strain of T. gondii (Reese et al.,
2011) revealed that pTg8E6.1 matched the ROP5 version IIC, a
protein of 549 amino acids (Figure 2C).
Identification of the Minimal Antigenic Peptide
To define the minimal antigenic peptide recognized by the
BTg45Z hybrid, we tested candidate peptides predicted to
bind Db MHC (Immune Epitope Database and Analysis
Resource, http://www.iedb.org/; Figure 3A). Analysis of cDNA
deletion constructs (Table 1) suggested that the antigenic
Figure 3. Identification of the Antigenic Epitope within ROP5IIC that
Stimulates BTg45Z Hybridoma
(A) Schematic representation of the N-terminal and C-terminal deletion con-
structs generated to identify the antigenic epitope within clone pTg8E6.1. The
clone was truncated andmissing the 50 UTR and nucleotides encoding the first
222 amino acids. The specific amino acids tested in each construct are shown
in parentheses and the antigenic activity region is indicated by the filled gray
circle. Open circles represent other putative H-2Db binding epitopes as pre-
dicted by the Immune Epitope Database (http://www.iedb.org/).
(B) BTg45Z lacZ response after an overnight stimulation to different deletion
constructs that were transfected in H-2Db expressing APCs.
(C) Sequences of antigenic peptide and its N-terminal extended versions.
BTg45Z lacZ response to BMDCs alone or BMDCs that were pulsed with
varying concentrations of the indicated peptides is shown.
See also Figures S2 and S3.activity mapped to the YAVANYFFL (YAL9) peptide (Figure 3B).
Moreover, the YAL9 peptide had higher antigenic activity relative
to N-terminally extended versions of the peptide (Figure 3C), and
was found in high-performance liquid chromatography (HPLC)-Cfractionated extracts of cells transfected with pTg8E6.1 (Fig-
ure S1). We conclude that ROP5IIC was processed by APCs to
the YAL9 peptide that was presented by MHC I H-2 Db and
recognized by BTg45Z T cells.
Presentation of YAL9Requires ProteasomeandTAPand
Is Partially Dependent on ERAAP
In the classical MHC class I presentation pathway, cytosolic pro-
teins are broken down into peptides by the proteasome and are
transported into the ER via TAP. In the ER, some peptides are
further processed by the aminopeptidase ERAAP and loaded
onto MHC class I molecules (Serwold et al., 2001). To assess
whether presentation of YAL9 peptide required the components
of the classic MHC-I presentation pathway, we infected BMDCs
from wild-type B6, TAP/, or ERAAP/mice and used them
as APCs to stimulate the BTg45Z hybridoma. The BTg45Z cell
response was completely abolished in TAP-deficient cells and
was strongly inhibited by the proteasome inhibitor lactacystin
(Figure S2). In contrast, loss of ERAAP only partially inhibited
BTg45z responses. Thus, presentation of YAL9 requires protea-
some processing in the cytoplasm and transport by TAP into
the ER, but is only partially dependent on further trimming by
ERAAP.
Detection of YAL9-Specific CD8 T Cells in
T. gondii-Infected Mice
We next assessed the contribution of YAL9-specific CD8 T cells
to the overall T cell response to the parasite. We orally infected
H-2b (C57BL/6) mice and determined the abundance of specific
T cells in the CD8 T cell repertoire at 4 weeks postinfection by
H-2Db-YAL9 MHC tetramer staining and intracellular cytokine
staining (ICCS) after ex vivo restimulation with the YAL9 peptide
(Figures 4A–4E). The YAL9-specific T cells, as measured by
ICCS, accounted for 0.3% of splenic CD8 T cells (Figure 4B).
Based on the 3.5% parasite-specific cells among the total
CD8 T cells, we estimate that 10% of parasite-specific CD8
splenocytes are specific for YAL9. Tetramer staining gave
a slightly higher value (0.5%) of YAL9-specific T cells among
splenic CD8 T cells, perhaps due to higher sensitivity of this
assay (Figure 4C). Among CD8 T cells in the brain, YAL9-specific
cells accounted for 1% of the CD8 response based on both
ICCS and tetramer staining, corresponding to 10% of the total
parasite-specific CD8 response as estimated by ICCS (Figures
4D and 4E). Analyses of mice that were immunized with irradi-
ated parasites gave similar results, with 0.5% of splenic CD8
T cells showing reactivity to the YAL9 peptide (Figures 4F–4H).
Thus, unlike the response to the GRA6-derived peptide HF10,
which dominates the CD8 T cell response to the parasites in
H-2d mice (Blanchard et al., 2008), the ROP5-derived YAL9
peptide is a detectable but minor component of the CD8 T cell
response in H-2b mice.
Immunization of H-2d mice with DCs pulsed with the single
HF10 peptide derived from the dense-granule protein GRA6 eli-
cited robust protection against challenge with live parasites
(Blanchard et al., 2008). To determine the protective potential
of the YAL9-specific CD8 T cells, we immunized B6 mice with
DCs pulsed with YAL9 peptide and challenged the mice with a
lethal dose of T. gondii. We observed no statistically significantell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authors 1719
Table 1. Oligonucleotide Primers for ROP5 Deletion Constructs
Construct Forward (50–30) Reverse (50–30)
DNDC-3 GATCCATGTTCACACCTGAAAACCTTTTCATTATGTGAT CTAGATCACATAATGAAAAGGTTTTCAGGTGTGAACATG
DNDC-5 GATCCATGAATGCGTGGCAACTGGGTCTTAGCATATGAT CTAGATCATATGCTAAGACCCAGTTGCCACGCATTCATG
DN-7 CGCGGATCCGCGATGGTCGGAACCCGAGGACCG GCTCTAGAGCAGCGACTGAGGGCGCAGC
DNDC-8 CGCGGATCCGCGATGGAGGAGGCACGG GCTCTAGAGCGCTTGATGCCGGTCCTCG
DNDC-9 CGCGGATCCGCGATGCCAGGACAGAGC GCTCTAGAGCGCTTGATGCCGGTCCTCGdifference in survival (Figure S3A), cyst number, or parasite load
(Figures S3H and S3I) between mice immunized with the YAL9
versus an irrelevant H-2Db binding peptide. These results are
consistent with evidence that the GRA6 response alone can ac-
count for the protective effect of MHC-class I H-2Ld expression
on an H-2d background (Brown et al., 1995; Blanchard et al.,
2008; Feliu et al., 2013), implying that none of the parasite anti-
gens presented by H-2b class I alleles provide as strong protec-
tion as H-2Ld-HF10.
Generation of Transgenic Parasites with Altered
Intracellular Trafficking of T Cell Epitopes
TheROP5 andGRA6 antigenic precursors differ in theirmodes of
secretion by T. gondii (Figure 5A). The ROP5 protein is secreted
into host cells during parasite invasion via secretory organelles
known as rhoptries, whereas GRA6 is constitutively secreted
into the parasitophorous vacuole through dense granules. To
assess the influence of differential protein targeting on T cell re-
sponses, we generated three hemagglutinin (HA)- or FLAG-
tagged constructs encoding type II ROP5 (the so-called IIC
allele) and GRA6 genes, along with constructs designed to
swap the secretion patterns of the antigenic ROP5 and GRA6
peptides (Figures 5B and S4). These constructs were (1)
GRA6-YAL9, which replaces the T cell epitope of GRA6 (HF10)
with that of ROP5 (YAL9) to target this normally rhoptry peptide
to dense granules; (2) GRA6-ROP5, which has the promoter and
signal peptide of the GRA6 gene (Gendrin et al., 2010) fused up-
stream of the C-terminal domain of ROP5, including the YAL9
epitope, thus also targeting the bulk of this rhoptry protein to
dense granules; and (3) ROP5-HF10, in which the HF10 epitope
of GRA6 is fused to the C terminus of ROP5, thus targeting this
normally dense-granule peptide for secretion via rhoptries.
We introduced these constructs as transgenes into the type III
parasite strain CTG, whose alleles of GRA6 and ROP5 do not
encode the YAL9 or HF10 T cell-stimulatory epitopes (Blanchard
et al., 2008; Reese et al., 2011; Feliu et al., 2013). To confirm
appropriate targeting of the proteins, we performed immunoflu-
orescence analysis of transgenic parasites (Figures S4B and
S4C). As expected, parasites expressing GRA6, GRA6-YAL9,
and GRA6-ROP5 all displayed transgenic protein colocalization
with the dense-granule marker GRA7 (Figures S4B and S4C),
whereas parasites expressing ROP5-HF10 displayed accumula-
tion of transgenic protein in structures that colocalizedwith rhop-
try markers ROP2, ROP3, and ROP4 (Figure S4B). On the other
hand, and also as expected, CTG harboring the wild-type ROP5
construct showed a typical rhoptry pattern of staining and failed
to localize with GRA7 (Figure S4C). Western blot analysis indi-
cated that GRA6-YAL9 was expressed at somewhat lower levels1720 Cell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authors(1/3) than what was seen for GRA6-ROP5 (Figure S4D). A com-
parison of the HA-tagged GRA6-ROP5 and the FLAG-tagged
ROP5 indicated that ROP5 was also expressed at a lower level
(1/5–1/10) relative to GRA6-ROP5 (Figure S4E). For the para-
site strains expressing the GRA6 epitope HF10, ROP5-HF10
levels were similar to those of transgenic GRA6 (Figure S4F).
The Immunogenicity of Antigenic Peptides Is Enhanced
by Targeting the Precursor Protein to Dense Granules
We next assessed the ability of transgenic parasites to stimulate
ROP5-specific or GRA6-specific T cells. We expected that the
parental CTG strain would not elicit a YAL9-specific T cell
response, since this strain harbors ROP5 alleles that lack this
antigenic epitope (Reese et al., 2011). To confirm this, we
measured the response of the BTg45Z hybridoma to DCs in-
fected with CTG parasites or pulsed with peptides derived
from the regions corresponding to the YAL9 peptide in the allelic
forms of ROP5 containedwithin the CTGparasites (Figures S5A–
S5C). As expected, we observed no detectable response to CTG
parasites or to these alternate ROP5 peptides. Interestingly, a
polymorphic peptide from another type II allele within the multi-
gene ROP5 locus (ROP5IIA, which is identical to YAL9 except for
a L substituting for a F at position 8) stimulated the hybridoma
comparably to what was seen with YAL9 from ROP5IIC (Fig-
ure S5C). However, and as predicted by their respective genome
sequences, neither the CTG nor the RH parasite strains ex-
pressed a form of ROP5 that stimulated our ROP5-specific hy-
bridoma (data not shown). We also confirmed that immunization
of mice with irradiated CTG parasites did not elicit a detectable
response to the YAL9 epitope as measured by both ICCS and
tetramer staining (Figures S5D and S5E).
To assess whether the immunogenicity of the YAL9 or
HF10 epitopes was affected by altering the secretion of the pre-
cursor protein, we infected DCs with the transgenic parasites
described above and measured peptide presentation using
the corresponding lacZ-inducible hybridoma. The ROP5-spe-
cific BTg45Z hybridoma response to transgenic CTG parasites
expressing either one of the dense-granule-targeted YAL9 con-
structs (GRA6-ROP5 and GRA6-YAL9) was substantially higher
than those expressing YAL9 in its native form, i.e., as a part of
ROP5IIC targeted to its normal location, the rhoptries (Figure 5C,
left panel). On the other hand, the GRA6-specific CTgEZ4
hybridoma response to parasites harboring the rhoptry-tar-
geted HF10 peptide (ROP5-HF10) was substantially reduced
compared with the response to the normally dense granule-tar-
geted version of the epitope (Figure 5C, right panel).
We compared the different transgenic parasite strains for their
ability to elicit CD8 T cell responses in vivo.We infectedmice and
Figure 4. YAL9-Specific CD8 T Cell Response Constitutes a
Detectable Fraction of the In Vivo T. gondii-Specific Response
(A–H) Mice were orally infected with 25–40 T. gondii cysts (A–E) or immunized
with irradiated 5 3 106 T. gondii, ME49 tachyzoites (F–H). Splenocytes and
brain leukocytes were harvested from mice 3–4 weeks after oral infection
or 2 weeks after immunization. T. gondii-specific T cell responses were
measured by intracellular cytokine staining for IFN-g or by staining with pep-
tide-MHC tetramers.
(A) Representative flow-cytometry plots of splenocytes from naive and in-
fected mice. Left panels show intracellular IFN-g staining after in vitro re-
stimulationwith APCs (either +/ T. gondii or 1 mMYAL9 peptide). Right panels
show MHC class I H-2Db-YAL9 tetramer staining.
(B and D) Compiled data showing T. gondii-specific and H-2Db-YAL9-specific
responses from (B) spleen and (D) brain of infected mice. Data are corrected
for background based on responses byCD8 T cells toward uninfected APCs or
APCs pulsed with irrelevant peptide. Each dot represents an individual mouse.
(C and E) Compiled data showing flow-cytometry analysis of MHC class I
H-2Db-YAL9 tetramer staining on (C) splenocytes and (E) brain leukocytes.
Cells were also costained with CD8 antibody.
(F) Representative flow-cytometry plots of splenocytes from naive and
immunized mice. Left panels show intracellular IFN-g staining after in vitro
restimulation with APCs either +/ T. gondii or 1 mM YAL9 peptide. Right
panels show MHC class I H-2Db-YAL9 tetramer staining.
(G) Compiled data showing splenic T. gondii-specific and H-2Db-YAL9-spe-
cific responses from immunized mice. Data are corrected for background
based on responses by CD8 T cells toward uninfected APCs or APCs pulsed
with irrelevant peptide. Each dot represents an individual mouse.
(H) Compiled data showing MHC class I H-2Db-YAL9 tetramer staining on
splenocytes from immunized mice. Cells were also costained with CD8 anti-
body. Data are representative of at least three independent experiments.
Data (mean and SEM) are representative of at least three independent
experiments. See also Figure S3.
Cexamined T cell responses in spleen and brain leukocytes at
3–4 weeks postinfection. At day 21 postinfection, ROP5-specific
T cells made up 0.5% of the total CD8 T cell population in the
spleen and brains of mice infected with type III CTG parasites
expressing the normally targeted ROP5 protein, similar to the
results obtainedwith the type II strains Pru andME49 (Figure 5D).
Strikingly, infection with CTG+GRA6-ROP5 parasites elicited a
10- to 20-fold higher YAL9-specific T cell response compared
with CTG+ROP5 parasites, as measured by tetramer staining
(Figure 5D). In spite of the increase in the number of specific
T cells in the brain, their expression of effector/memory markers
KLRG-1 and IL7R remained unchanged (Figure 5E). In addition, a
comparison of the YAL9-specific versus parasite-specific CD8
T cells using in vitro restimulation and intracellular IFN-g staining
revealed that the YAL9-specific T cell response accounted for
the bulk of the antiparasite CD8 response in mice infected with
CTG+GRA6-ROP5 parasites (Figure 5F). This predominance of
the YAL9-specific response resulted in a significant decrease
in the CD4-to-CD8 ratio among parasite-specific IFN-g produc-
ing T cells in both the spleen and brain (Figure 5G). The YAL9-
specific CD8 T cell response to the CTG+GRA6-YAL9 strain
was also enhanced compared with CTG+ROP5, although to
a lesser extent than with CTG+GRA6-ROP5 parasites (Figures
5D, 5F, and 5G). A similar enhancement of the CD8 T cell
response to dense granule-targeted YAL9 was also observed
when mice were immunized with irradiated transgenic parasites
(Figures 5H and 5I).
We observed a similar correlation between enhanced T cell
response and dense-granule targeting with the GRA6 epitopeell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authors 1721
(legend on next page)
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(Figure 5J). GRA6-specific T cells constituted 10% of the total
CD8 T cell population in the spleen and 30% in the brains of mice
infected with CTG parasites expressing the normally targeted
GRA6 protein, similar to the results obtained with the type II
strain Pru (Figure 5J). In contrast, mice infected with parasites
harboring the rhoptry-targeted version of the GRA6 epitope
(ROP5-HF10) had 3- to 4-fold lower numbers of GRA6-specific
T cells. Together, these data indicate that the same T cell epitope
evokes a greater T cell response when secreted via dense gran-
ules versus rhoptries.
YAL9-Specific T Cells Provide Protection against
Parasites in which the Epitope Is Targeted to Dense
Granules
In some settings, CD8 T cells may be expanded effectively but
still fail to provide strong protection (Shen et al., 1998). To deter-
mine whether retargeting of the YAL9 epitope could enhance im-
mune protection as well as CD8 expansion, we examined the
ability of peptide-DC immunization to provide protection against
transgenic parasites in which the YAL9-containing protein was
targeted for secretion via dense granules versus rhoptries. We
performed peptide immunization with YAL9 in mice according
to the scheme in Figure 6A, and challenged them intraperitone-
ally (i.p.) with a high dose of CTG+ROP5 or CTG+GRA6-ROP5
transgenic parasites. Strikingly, all of the mice that were immu-
nized with YAL9 and then challenged with CTG+GRA6-ROP5Figure 5. Enhanced T Cell Response when the Antigenic Precursor Pr
(A) Schematic depicting distinct modes of secretion for the dense-granule protei
(depicted in blue). Also shown are possible routes for antigen processing and pre
during invasion. ROP5 associates with the cytosolic face of parasitophorous v
dense-granule proteins into the PV lumen of invaded host cells. Proteolytic proces
the proteasome, and further trimming by ERAAPmay occur after TAP-mediated tra
I molecules to be transported to the cell surface for recognition by a CD8 T cell (
(B) Left-hand diagrams show wild-type ROP5 and GRA6 genes, indicating the lo
FLAG epitope tags. Right-hand diagrams show the transgenic constructs used t
ments. GRA6-YAL9 has the HF10 epitope of theGRA6 gene replaced by YAL9. An
to allow for efficient processing (not depicted). GRA6-ROP5 contains the GRA6
gene including the YAL9 epitope. ROP5-HF10 contains the HF10 epitope fromGR
transgenes into the parental type III strain, CTG, which harbors allelic forms of R
(C) BMDCs from C57BL/6 (H-2b) or B10.D2 (H-2d) mice were infected in vitro wit
CTgEZ.4 lacZ response was measured after an overnight stimulation with BMDC
(D) C57BL/6 mice (H-2b) were infected i.p. with 105 transgenic T. gondii tachyz
postinfection, and T. gondii-specific T cell responses were measured by staining w
on gated CD8+ B220 splenocytes (left panel) and brain leukocytes (right panel
(E) Compiled data showing percent expression of the effector T cell marker KLRG
specific CD8 T cells frommice infected by 105 transgenic parasites i.p. Brain leuko
an average from four to five mice. Data (mean and SEM) are pooled from two ind
(F) Compiled data showing splenic (left panel) and brain (right panel) T. gondii-s
measured by intracellular cytokine staining for IFN-g. Data are corrected for backg
with irrelevant peptide.
(G) Plots depicting the ratio of T. gondii-specific CD4-to-CD8 T cell response fro
(H) Mice were immunized with irradiated 5 3 106 transgenic T. gondii tachyzoit
T. gondii-specific T cell responses were measured using intracellular staining fo
responses from immunized mice. Data are corrected for background based on
peptide.
(I) Compiled data showing MHC class I H-2Db-YAL9 tetramer staining on splenoc
bar represents an average from six mice. Each dot represents an individual mou
(J) B6xB6.C (H-2b/d) mice were infected with the indicated transgenic T. gondii tac
postinfection and GRA6-specific T cell responses were measured by staining w
B220 splenocytes (left panel) and CD8+ brain leukocytes (right panel). *p < 0.0
See also Figures S4 and S5.
Csurvived the acute phase of infection. In contrast, the majority
of mice that were immunized with YAL9 peptide and then chal-
lengedwith CTG+ROP5, or were immunizedwith control peptide
(WI9), succumbed to infection within the first week after chal-
lenge (Figure 6B). Thus, the combination of peptide immuniza-
tion to create a preexisting ROP5-specific T cell population
and challenge with parasites harboring the epitope targeted for
secretion via dense granules provided strong immune protection
during the acute phase of infection.
To further explore the mechanism of protection, we measured
the T cell responses in the chronic phase of infection in the
surviving mice (Figures 6C–6E). Interestingly, there was an
enhanced YAL9-specific response in the brains of CTG+GRA6-
ROP5-infected animals irrespective of the peptide immunization.
This difference was seen as an increased proportion of YAL9-
specific CD8 T cells based on tetramer staining (Figure 6C),
ex vivo restimulation followed by ICCS for IFN-g (Figure 6D),
and an overall decrease in the CD4-to-CD8 ratio among INF-g-
producing, T. gondii-specific T cells (Figure 6E). Similar trends
were observed in the splenic T cells of surviving mice (Figures
S6A–S6C). We also observed a marked difference in the cyst
load of surviving mice chronically infected with CTG+ROP5 rela-
tive to CTG+GRA6-ROP5, regardless of the peptide immuniza-
tion (Figure 6F). This difference is likely due to a more protective
CD8 T cell response rather than to reduced overall fitness of
the parasite strains, since CTG+GRA6-ROP5, CTG+GRA6, andoteins Are Targeted to Parasite Dense Granules
n GRA6 (depicted in red) (Holtappels et al., 2008) versus rhoptry protein ROP5
sentation via MHC-I. T. gondii injects rhoptry proteins directly into the host cell
acuole membrane (PVM) following secretion. Parasites constitutively secrete
sing of parasite secretory proteins could take place in the host cells’ cytosol by
nsport of peptides into the ER. Processed peptides are loaded ontoMHCclass
not depicted).
cation of their antigenic epitopes (YAL9 and HF10) and placement of HA and
o retarget expression of the epitopes to different parasite secretory compart-
additional ten amino acids fromROP5 flanking the YAL9 epitope were included
promoter and signal sequence fused to the C-terminal portion of the ROP5IIC
A6 fused to the C terminus of ROP5IIIC gene. All constructs were introduced as
OP5 and GRA6 that lack the T cell stimulatory epitopes.
h irradiated transgenic T. gondii tachyzoites at varying MOIs, and BTg45Z and
s ± T. gondii.
oites. Splenocytes or brain leukocytes were harvested from mice 3–4 weeks
ith tetramers. Compiled data showMHC class I H-2Db-YAL9 tetramer staining
).
-1 and memory T cell marker IL7R in brain T. gondii-specific and H-2Db-YAL9-
cytes were harvested frommice at 3 weeks postinfection. Each bar represents
ependent experiments.
pecific and H-2Db-YAL9-specific CD8 T cell responses from infected mice as
round based on responses by T cells toward uninfected APCs or APCs pulsed
m spleen (left panel) or brain (right panel) of infected mice.
es. Splenocytes were harvested from mice at 2 weeks postimmunization and
r IFN-g. Compiled data show splenic T. gondii and YAL9-specific CD8 T cell
responses by T cells toward uninfected APCs or APCs pulsed with irrelevant
ytes from immunized mice. Cells were also costained with CD8 antibody. Each
se. Data (mean and SEM) are pooled from two independent experiments.
hyzoites. Splenocytes or brain leukocytes were harvested frommice at 21 days
ith H-2Ld-HF10 tetramers. Compiled tetramer staining data on gated CD8+
5, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 6. Enhanced Protection when the
YAL9 Epitope Is Targeted to Parasite Dense
Granules
(A) Mice were immunized with lipopolysaccha-
ride-activated BMDCs pulsed with YAL9 or
control peptide (WI9), boosted after 2 weeks, and
after 3 weeks challenged with 5 3 105 live trans-
genic T. gondii tachyzoites i.p. (either CTG+ROP5
or CTG+GRA6-ROP5).
(B) Kaplan-Meier survival curves among the four
groups of mice.
(C–F) Mice that survived the acute phase
of infection were sacrificed at 7 weeks after
challenge.
(C) MHC class I H-2Db-YAL9 tetramer staining on
brain leukocytes from surviving mice. Cells were
also costained with CD8 antibody.
(D and E) CD8 T cells (D) and ratio of T. gondii-
specific CD4-to-CD8 T cells in the brain (E) as
measured by ICCS for IFN-g using flow cytometry
after ex vivo restimulation with T. gondii-infected
APCs or peptide-pulsed APCs. Data are back-
ground corrected based on the values from
uninfected APCs or APC pulsed with irrelevant
peptide.
(F) Number of cysts in the brain as measured by
staining a portion of the brain with fluorescent
lectin to detect the cysts. Data (mean and SEM)
are pooled from two representative experiments
with at least five mice per condition in each
experiment. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001; NS, not significant.
See also Figure S6.CTG+ROP5 transgenic parasites all displayed similar growth in
TAP/ mice, which lack a functional CD8 T cell response
(data not shown). These data indicate that the YAL9-specific
CD8 T cells generated upon challenge with CTG+GRA6-ROP5
parasites can eventually expand and predominate in the brain
and control parasites during the chronic phase of infection, pro-
vided that the mice can survive the acute phase. Moreover, the
generation of preexisting YAL9-specific T cells by peptide immu-
nization can allow for survival of acute infection, but only when
the mice are challenged with parasites expressing the dense
granule-targeted YAL9. These data imply that both superior
T cell expansion and superior protection contribute to the effi-
cacy of the CD8 T cell response to dense granule-targeted
YAL9. Moreover, these results imply that constitutively secreted
endogenous parasite antigens provide better target antigens to
elicit protective CD8 responses.
DISCUSSION
Intracellular protozoan parasites possess distinct secretory
pathways by which they introduce their proteins into infected
host cells, thus providing a means of immune detection by
CD8 T cells. However, the impact of regulated secretion on
CD8 T cell responses is not known. Here, we have identified a
relatively ineffective CD8 T cell response in the susceptible
(H-2b) strain of mice that is directed toward a peptide (YAL9)
derived from the parasite protein ROP5. ROP5 originates in
the rhoptries and is injected directly into the cytoplasm of the1724 Cell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authorshost cell during invasion, whereas the highly protective antigen
GRA6 is a dense-granule protein that is constitutively secreted
into the lumen of the parasitophorous vacuole. To test the
hypothesis that the mode of protein secretion contributes to
the difference in the CD8 response between ROP5 and GRA6,
we engineered parasites in which the epitopes from ROP5
and GRA6 were altered in their secretion pattern. Strikingly,
parasites in which the ROP5 epitope was secreted via dense
granules elicited a much greater CD8 T cell response, whereas
targeting the GRA6 epitope to rhoptries led to decreased re-
sponses. Moreover, the combination of immunizing mice with
the ROP5 epitope and retargeting the ROP5 epitope to dense
granules led to strong protection. These data will help to unravel
the differences between effective and weak CD8 T cell re-
sponses, and have important implications for host-pathogen in-
teractions and the design of CD8 vaccines against intracellular
parasites.
Why does targeting epitopes to dense granules lead to
improved CD8 T cell responses? Although we cannot exclude
the possibility that this effect is due solely to higher overall levels
of the precursor protein, we believe this is unlikely, since endog-
enous ROP5 is already among the most highly expressed pro-
teins in Toxoplasma (Toxoplasma Genomics Resource, http://
toxodb.org/toxo/) but evokes a relatively weak T cell response.
In addition, although increased protein levels may contribute to
the enhanced CD8 response elicited by the dense-granule-tar-
geted GRA6-ROP5, this is not the case for another dense-
granule-targeted version of the ROP5 epitope, GRA6-YAL9,
which is expressed at similar levels to the rhoptry-targeted ROP5
transgene but also elicits a stronger response. Moreover, the
dense-granule-targeted GRA6 protein evokes a substantially
higher T cell response compared with the rhoptry-targeted
version of the same epitope ROP5-HF10, although both precur-
sor proteins are expressed at similar levels. In addition, since
only certain pools of parasite proteins enter host cells and
become accessible to the class I MHC processing pathway,
there may be little correlation between the amount of precursor
protein in the parasite and the number of peptides that are ulti-
mately displayed on the host cell surface. Lastly, although in
some settings there is a correlation between antigen expression
levels and the magnitude of the CD8 T cell response, this is not
always the case. Indeed, some studies have revealed little corre-
lation among the expression levels of the antigenic precursor
protein, the amount of peptide that is displayed, and the magni-
tude of the CD8 responses (Croft et al., 2013; Dolan et al., 2011;
Neefjes et al., 2011; Schwab et al., 2003).
A more likely explanation is that enhanced CD8 recognition is
related to the altered spatial and/or temporal pattern of entry of
the precursor protein into host cells. For example, whereas rhop-
try release provides a single bolus of precursor protein during
invasion, constitutive secretion via dense granules may eventu-
ally lead to a greater accumulation of the antigenic precursor
protein in the infected cell, and ultimately to a higher density of
peptide-MHC complexes displayed on the host cell surface.
With regard to the spatial pattern of antigen entry into host
cells, at first glance it might be predicted that rhoptry targeting
would favor CD8 T cell responses, since parasite proteins are
directly secreted into the host cytosol and thus should be able
to directly enter the classical MHC-I presentation pathway
without crossing a membrane. However, reports of a direct
interaction between the parasitophorous vacuole and the host
ER could provide an efficient route for cross-presentation of
dense-granule-targeted antigens (Goldszmid et al., 2009),
thus offsetting this potential advantage of rhoptry-targeted
antigens.
It is also interesting to consider that rhoptry versus dense-
granule targeting may also have an impact on the spatial distri-
bution of host cells presenting parasite antigens in vivo. This
notion stems from the observation that parasites can secrete
rhoptry contents into host cells in the absence of productive in-
vasion (Koshy et al., 2010). Indeed, a recent study that used par-
asites expressing a rhoptry-targeted CRE reporter andmice with
a CRE-inducible fluorescent reporter revealed that a much
greater number of host cells had activated the reporter, and
thus had received parasite rhoptry proteins, compared with
host cells harboring parasites (Koshy et al., 2012). Thus, one
could envisage that CD8 T cell antigens that are targeted for
secretion via rhoptries would be presented more broadly in vivo,
including on host cells that do not harbor parasites. Such a
mechanism could help to explain the poor protection of CD8
T cells directed against rhoptry-derived antigen, since the result-
ing CD8 effector T cells could be distracted by interacting with
noninvaded host cells rather than delivering protective cytokines
to infected cells where they are most needed. Misdirected CD8
effector responses also lead to increased collateral damage by
T cells, although the correlation between decreased protectionCand increased parasite load argues against this as amajormech-
anism in this setting.
Although our data indicate that the mode of secretion has an
important impact on CD8 responses, this does not imply that
secretion is the sole determinant of antigenicity. Indeed, some
parasite antigens derived from dense-granule proteins do not
trigger strongly immunodominant CD8 T cell responses (Frickel
et al., 2008). Other factors, including the route of protein traf-
ficking after secretion, the C-terminal position of the epitope
within the source antigen (Feliu et al., 2013), the ability of the pep-
tide to bind MHC, and the affinity and precursor frequency of the
responding T cells (Kotturi et al., 2008; Moon et al., 2007; Obar
et al., 2008), will undoubtedly have an impact as well. Moreover,
although most CD8 T cell responses appear to be targeted to
invaded host cells (Goldszmid et al., 2009; Gubbels et al.,
2005), the ability of particular antigens to be efficiently cross-
presented by noninvaded bystander cells could potentially pro-
mote strong CD8 T cell responses independently of the mode
of secretion from the parasite (Mashayekhi et al., 2011).
Apicomplexan parasites, including the disease-causing
agents Plasmodium spp., Cryptosporidium, and Toxoplasma,
use distinct secretory organelles to deliver parasite effector mol-
ecules into the host cells and thereby manipulate host cell phys-
iology. Entry of parasite effector proteins into host cells can
potentially alert the host to the presence of an intracellular path-
ogen, and act as an ‘‘Achilles heel’’ for the parasite. Therefore,
knowledge of how the secretion pattern affects CD8 T cell re-
sponses is important for the design of effective vaccines against
these agents. In particular, there is intense interest in developing
vaccines that elicit CD8 T cell responses to the pre-erythrocytic
form of the malaria parasite Plasmodium. Although proteomic
and genomic analyses have yielded a large number of possible
candidate targets, screening and prioritizing these candidates
remains amajor challenge (Duffy et al., 2012; Hill, 2011; Vaughan
and Kappe, 2012). Our data indicate that determining the mode
of secretion of potential vaccine targets may be a powerful
approach to narrow the list of vaccine candidates, and that anti-
gens that reside within parasite dense granules may be particu-
larly promising candidates, whereas rhoptry proteins should be
avoided. In addition, our results may aid in the design of more
effective vaccine strains of Toxoplasma gondii, an approach
that is currently being explored to promote antitumor immunity
(Baird et al., 2013).
EXPERIMENTAL PROCEDURES
Mice
B6.C, C57BL/6 (B6), B10.D2, DBA, CBA, MHC class II-deficient B6.129S-
H2 dlAb1-Ea, and TAP-deficient B6.129S2-Tap1tm1Arp/J mice were obtained
from The Jackson Laboratory. B6xB6.C (H-2b/d), MHC class II-deficient
B6.129S-H2 dlAb1-Ea and TAP-deficient B6.129S2-Tap1tm1Arp/J mice were
then bred at the UC Berkeley animal facility. H-2b ERAAP-deficient mice on
theC57BL/6 background have been described previously (Hammer et al.,
2006). For all immunization and infection experiments, sex- and age-matched
mice were used. Mice were used with the approval of the Animal Care and Use
Committee of the University of California.
Generation of Transgenic Parasites
Transgenic parasites were generated using the type III strain CTGDhxgprt
(Donald et al., 1996), engineered to express luciferase and GFP. For theell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authors 1725
ROP5 construct, DNA sequences encoding ROP5IIC, including its native pro-
moter, were cloned into pHXGPRT adjacent to the HXPGRT cassette and in
frame with a C-terminal 3x FLAG. For the ROP5-HF10 construct, the promoter
and coding regions of the type III ROP5C allele were fused to a C-terminal HA-
tag and GRA6 epitope HF10 (HPGSVNEFDF). For the GRA6 construct, DNA
sequences encoding GRA6 type II, including its native promoter and entire
coding region, were modified by the addition of an HA epitope between amino
acids 50 and 51 of GRA6. For the GRA6-YAL9 construct, the last ten amino
acids (HF10) of GRA6 were replaced by the amino acids FAQLSPGQSD
YAVANYFFL (where the underlined residues represent the epitope YAL9
from ROP5 type IIC). The GRA6 construct was also used as the starting
plasmid for generation of GRA6-ROP5, wherein DNA sequences encoding
the pseudokinase domain of ROP5 type IIC (Reese et al., 2011) were amplified
and cloned downstream of the native GRA6 type II promoter, GRA6 coding
sequence up to residue 50, and an in-frame HA tag. The transgenic strains
were made by electroporation of linearized plasmids as described previously
(Donald et al., 1996).
In Vivo Infection and Immunization
Mice were immunized i.p. with 1–5 3 106 irradiated tachyzoites of the type II
Prugniuad-tomato-OVA strain (Pru) as described previously (Grover et al.,
2012). To induce protection, mice were immunized in the footpad with
activated B6 BMDCs loaded with synthetic peptide as described previously
(Blanchard et al., 2008). After 7–14 days, the mice were given the same
dose for boost and then infected 21 days after boost with a lethal dose of
live Pru tachyzoites (1 3 104 to 5 3 105) i.p. For chronic infections, the mice
were orally fed 25–50 cysts of the Pru strains or by i.p. injection of (5 3 103
to 5 3 105) live tachyzoites from parental or transgenic CTG strains. Cysts
were obtained from CBA mice infected for 3–5 weeks i.p. with live 400 Pru
tachyzoites. Parasite load was analyzed by semiquantitative PCR (Kirisits
et al., 2000) or by counting individual labeled cysts as described previously
(Grover et al., 2012).
Ex Vivo Analysis
Mice were euthanized at 3–7weeks postinfection or 1–2weeks postimmuniza-
tion. Spleen and brain leukocyte populations were prepared as previously
described (Blanchard et al., 2008). The proportion of T. gondii-specific or
antigen-specific cells was monitored by ICCS for IFN-g on CD4+ or CD8a+
cells. APCs were either infected the day before or pulsed with antigenic
peptide on the same day and used for the ex vivo IFN-g assay. Antigen-
specific CD8a+cells were also detected via staining using MHC class I peptide
tetramers (see below).
Generation of Toxoplasma gondii-Specific T Cell Hybridomas
C57BL/6 mice were immunized with 13 106 irradiated Pru tachyzoites (14,000
rads) i.p. Mice were euthanized at 7 days postinfection and spleens were
dissociated into single-cell suspensions. T. gondii-specific populations were
expanded in vitro by weekly restimulations with irradiated syngeneic spleno-
cytes or irradiated MHC class II-deficient, B6.129S-H2 dlAb1-Ea BMDCs
(2,000 rads) that were infected with irradiated Pru tachyzoites the day before.
After 8 weeks of in vitro restimulation, T cells were fused to a TCRab-
negative, lacZ-inducible BWZ.36.CD8a fusion partner, allowing T cell hybrid-
oma activation to be measured by the lacZ response (Malarkannan et al.,
2001). The antigen specificity and MHC restriction of the hybridomas were
assessed by overnight incubation with infected or uninfected BMDCs from
wild-type C57BL/6 mice in the presence of MHC class I blocking antibodies
(Anti-H-2Kb antibody clone: 5F1.5; anti-H-2Db antibody clone: B22.249).
Expression Cloning
Bacteria were transformed with the T. gondii cDNA library cloned in pcDNA
(Blanchard et al., 2008), and DNA from bacterial transformants (9 cfu/well)
was screened to identify the antigen recognized by the T cell hybridoma as
described previously (Blanchard et al., 2008). To further identify antigenic pep-
tides, reverse-phase HPLC was used to separate extracts (Blanchard et al.,
2008) from COS-7 cells transfected with pTg8E6.1 or pcDNA. Before fraction-
ation, 10 pmol of the antigenic peptide YAL9 was added to the untransfected
COS-7 extracts. HPLC fractions were collected in 96-well plates, dried, and1726 Cell Reports 7, 1716–1728, June 12, 2014 ª2014 The Authorsanalyzed for antigenicity by addition of 5 3 104 APCs/well and 1 3 105 T cell
hybridoma/well.
In Vitro Differentiation and Infection
Bone marrow cells obtained from mouse femurs and tibias were differentiated
into DCs as described previously (Grover et al., 2012). After differentiation, the
BMDCs were infected overnight with irradiated tachyzoites (14,000 rads) at
variousmultiplicities of infection (MOIs). The next day, cells were washed twice
to remove any extracellular parasites and were used in the assays.
Proteasome Inhibition
Proteasome inhibitor lactacystin was titrated (10 mM to 0 mM) onto 96-well
plates containing 5 3 104 BMDCs/well in complete RPMI media. Cells were
incubated with the inhibitor for 2 hr at 37C followed by the addition of
irradiated tachyzoites. At 8 hr postinfection, the media were removed from
treated and infected BMDCs and replaced with fresh complete media, with
the addition of 1 3 105 T cell hybridoma/well.
Flow Cytometry
Surface staining with anti-mouseCD4 (RM4-5), CD8a (53-6.7), IFN-g (XMG1.2;
BD Biosciences), and anti-mouse KLRG-1 and IL7R (eBiosciences or
BioLegend) antibodies was done according to themanufacturer’s instructions.
Intracellular cytokine staining for IFN-g was performed using the Cytofix/
Cytoperm kit (BD PharMingen). The concentration and time of staining of the
fluorescently labeled MHC class I tetramers bound to T. gondii antigenic
peptide (NIH Tetramer Facility) were optimized and cells were incubated
with the tetramer at 4C for 1 hr. The cells were then washed and followed
by surface staining at 4C for 30 min with anti-mouse CD4 or CD8a, B220
(CD45R), KLRG-1, and IL7R antibodies. All flow-cytometry data were acquired
on an XL Analyzer or FC 500 (Coulter) or BD LSRII and analyzed using FlowJo
software (Tree Star).
Western Blotting and Immunofluorescence Analysis
Parasites were harvested from infected human foreskin fibroblasts (HFFs) by
scraping, passaging through a 27 g needle, and filtering through a 5 mm filter.
They were then washed in PBS and resuspended in either Laemmli buffer with
dithiothreitol or NP-40 buffer (25 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.1%
NP40 + protease inhibitors). Proteins were separated by 10% SDS-PAGE
and transferred to PVDF membrane. Membranes were probed with rat anti-
HA antibody directly conjugated to horseradish peroxidase (HRP; Roche
3F10) or mouse monoclonal (M2) anti-3xFLAG (Sigma), and then rabbit
anti-SAG1 or rabbit anti-GRA7, and probed with HRP-conjugated secondary
antibodies. HRP levels were detected by chemiluminescence on film, followed
by densitometric analysis (ImageJ, NIH; as described on the How to Western-
Blot website, http://howtowesternblot.net/data-analysis-3/quantification/).
For protein localization, immunofluorescence of T. gondii-infected HFF cells
was performed as described previously (Koshy et al., 2012). After membrane
permeabilization, HA-tagged proteins were detected by rat anti-HA (Roche)
followed by fluorescently conjugated goat anti-rat IgG (Invitrogen). FLAG-
tagged proteins were detected with mouse monoclonal (M2) anti-3xFLAG
(Sigma) followed by Alexa Fluor 488-conjugated goat anti-mouse IgG
(Invitrogen). Rhoptries were marked using mouse anti-ROP2, -ROP3, -ROP4
antibody followed by Alexa Fluor 650-conjugated goat anti-mouse IgG
(Invitrogen). Dense granules were marked using rabbit anti-GRA7 followed
by Alexa Fluor 650-conjugated goat anti-rabbit IgG (Invitrogen). Images
were acquired by standard microscopy at 6003 or 1,0003 magnification
with minimal and equal processing in ImageJ (NIH).
Statistical Analysis
We calculated p values using the two-tailed Student’s (nonparametric) t test or
one-way ANOVA with Bonferroni post test in Prism (GraphPad).
SUPPLEMENTAL INFORMATION
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